Maria Antonia Coccia-Portugal
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Nuciforo P, Townend J, Piccart M, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia A, Gomez H, Gombos A, Coccia-Portugal M, Tseng L, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. Eur J Cancer 2022; 181:92-101.
Dec 27, 2022Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Dec 27, 2022Eur J Cancer 2022; 181:92-101
Nuciforo Paolo, Townend John, Piccart Martine, Fielding Shona, Gkolfi Panagiota, El-Abed Sarra, de Azambuja Evandro, Werutsky Gustavo, Bliss Judith, Moebus Volker, Colleoni Marco, Aspitia Alvaro Moreno, Gomez Henry, Gombos Andrea, Coccia-Portugal Maria Antonia, Tseng Ling-Ming, Kunz Georg, Lerzo Guillermo, Sohn Joohyuk, Semiglazov Vladimir, Saura Cristina, Kroep Judith, Ferro Antonella, Cameron David, Gelber Richard D, Huober Jens, Di Cosimo Serena
Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab
Ligorio F, Huober J, Moscetti L, Janni W, Coccia-Portugal M, Corsetto P, Belfiore A, Lorenzini D, Daidone M, Vingiani A, Gianni L, Pupa S, Bianchini G, Pruneri G, Nuciforo P, de Azambuja E, Izquierdo M, Di Cosimo S, Verderio P, Ciniselli C, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Vernieri C. Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab. J Natl Cancer Inst 2022
Jul 5, 2022Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab
Jul 5, 2022J Natl Cancer Inst 2022
Ligorio Francesca, Huober Jens, Moscetti Luca, Janni Wolfgang, Coccia-Portugal Maria Antonia, Corsetto Paola Antonia, Belfiore Antonino, Lorenzini Daniele, Daidone Maria Grazia, Vingiani Andrea, Gianni Luca, Pupa Serenella Maria, Bianchini Giampaolo, Pruneri Giancarlo, Nuciforo Paolo, de Azambuja Evandro, Izquierdo Miguel, Di Cosimo Serena, Verderio Paolo, Ciniselli Chiara Maura, Pizzamiglio Sara, Castagnoli Lorenzo, Dugo Matteo, Galbardi Barbara, Salgado Roberto, Loi Sherene, Michiels Stefan, Triulzi Tiziana, Tagliabue Elda, El-Abed Sarra, Vernieri Claudio
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Fumagalli D, Di Cosimo S, de Azambuja E, de la Pena L, Nuciforo P, Brase J, Huober J, Baselga J, Piccart M, Loi S, Coccia-Portugal M, Chang T, Gomez H, Venet D, Ignatiadis M, Azim H, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Sotiriou C. RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 2017; 3:227-234.
Feb 1, 2017RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Feb 1, 2017JAMA Oncol 2017; 3:227-234
Fumagalli Debora, Di Cosimo Serena, de Azambuja Evandro, de la Pena Lorena, Nuciforo Paolo, Brase Jan C, Huober Jens, Baselga José, Piccart Martine, Loi Sherene, Coccia-Portugal Maria Antonia, Chang Tsai-Wang, Gomez Henry, Venet David, Ignatiadis Michail, Azim Hatem A, Maetens Marion, Rothé Françoise, Salgado Roberto, Bradbury Ian, Pusztai Lajos, Harbeck Nadia, Sotiriou Christos